8-K/A: Apimeds Amends Merger, Securities Pacts; Boosts MindWave Equity

Apimeds Pharmaceuticals US, Inc. filed an amendment to correct clerical errors in its Merger Agreement and Certificate of Designation, and modified a Securities Purchase Agreement.

Summary

• Amendment No. 1 to Form 8-K corrects scriveners errors in the Agreement and Plan of Merger and the Certificate of Designation.
• The corrected Merger Agreement removes Sections 2.05(b) and 2.05(d) and related cross-references, as MindWave Innovations Inc. (the Company) did not have the right to appoint directors.
• The Common Stock Cap in Section 3.01(b) of the Merger Agreement was corrected from 29.9% to 0% of Acquiror Common Stock issued and outstanding.
• The Acquiror Preferred Stock issuable to holders of Existing Company Common Stock was corrected from 61% to 90.9% of total issued and outstanding equity securities of the Acquiror (calculated on a fully diluted basis).
• The corrected Certificate of Designation states the number of Series A Convertible Preferred Stock shares is 7,477,017, up from the previously stated 7,263,865 shares.
• Amendment No. 1 to the Securities Purchase Agreement clarifies the prohibition period for variable rate transactions, expands investor notification rights for funding events, and extends the date for the Acquiror to complete the Initial Closing.
• The Merger involves Apimeds Merger Sub, Inc. merging into MindWave Innovations Inc., with MindWave as the surviving corporation.
• Existing Company Stockholders will receive Acquiror Preferred Stock, collectively representing 90.9% of Acquiror's equity capital on an as-converted and fully diluted basis.
• A reverse stock split of Acquiror Common Stock at a 1-for-10 ratio is approved.
• The Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan will be amended to increase shares to 2,096,679.
• A new officer position of President will be created, with Erik Emerson appointed as President of the Acquiror.
• The individual serving as CEO of Acquiror immediately prior to the Effective Time will cease to hold office, and an individual designated by the Company will be appointed as the new CEO.
• Bio Sub (Lokahi Therapeutics, Inc.) will continue the clinical-stage biopharmaceutical business of Apitox.
• Acquiror will use best efforts to consummate a private placement offering of up to $120,900,000.
• If the private placement is not consummated by closing, Bio Sub will provide a $2,500,000 loan to the Company for TechyTrade's operational purposes.

Sentiment

Score: 6

Explanation: The filing primarily concerns corrections of clerical errors and clarifications of existing agreements, which are generally neutral events. The increase in MindWave's post-merger ownership (from 61% to 90.9% of Acquiror's equity on a fully diluted basis) is a significant positive for MindWave's existing shareholders. The capital raise efforts and the extension of the closing date for the initial funding are positive for operational flexibility, though the need for a bridge loan from Bio Sub suggests potential short-term funding gaps. The correction of errors, while necessary, indicates initial oversight.

Positives

• Correction of clerical errors ensures accuracy of merger terms and share designations, reducing future legal or financial discrepancies.
• Increased ownership for existing Company (MindWave Innovations Inc.) stockholders in the combined entity (90.9% vs. 61% previously stated) on a fully diluted basis, indicating a more favorable equity split for the acquired entity's shareholders.
• Clarification of terms in the Securities Purchase Agreement, including investor notification rights and variable rate transaction prohibitions, enhances transparency and investor protection.
• Extension of the Initial Closing date in the Securities Purchase Agreement provides more flexibility for the Acquiror to complete financing.
• Commitment to maintain directors and officers liability insurance for six years post-merger provides continuity of protection for key personnel.
• Dedicated funding and operational preservation for the Bio Business (Apitox development) through Bio Sub ensures the continuation of this clinical-stage biopharmaceutical initiative.
• Appointment of a new CEO for Acquiror (designated by the Company) and Erik Emerson as President could bring new leadership and strategic direction to the combined entity.

Negatives

• Initial errors in the Merger Agreement and Certificate of Designation required an amendment, indicating potential oversight in initial drafting or review processes.
• The Common Stock Cap for existing Company stockholders was corrected from 29.9% to 0%, meaning no Acquiror Common Stock will be issued directly to them at closing, only preferred stock convertible to common, which might be perceived as less immediate liquidity.
• The need for a $2.5 million loan from Bio Sub to TechyTrade if the private placement is not consummated by closing suggests potential short-term liquidity needs for the acquired entity.
• The 'Premium Cap' for D&O insurance (350% of current annual premiums) could limit coverage if costs exceed this cap, potentially leaving some risk unmitigated.

Risks

• Integration Risk: Potential challenges in integrating MindWave Innovations Inc. and its operations with Apimeds Pharmaceuticals US, Inc.
• Financing Risk: The private placement offering of up to $120.9 million may not be fully consummated, impacting the combined entity's capital.
• Regulatory Compliance Risk: Failure to obtain or maintain NYSE American listing approval for the combined entity or its securities.
• Operational Risk for Bio Business: The Bio Business (Apitox development) is subject to the inherent risks of clinical-stage biopharmaceutical development, including trial failures and regulatory hurdles.
• Shareholder Dilution: Future conversion of Acquiror Preferred Stock into Common Stock could dilute existing Acquiror Common Stockholders.
• Litigation Risk: Any undisclosed or threatened material Actions against the Company or Acquiror could impact the combined entity.
• Intellectual Property Risk: Challenges to the ownership, validity, or enforceability of Intellectual Property, or claims of infringement, could arise.
• Data Protection Risk: Loss, theft, or unauthorized access to Personal Information could lead to material liability.
• Market Value Risk: The 'then applicable market value' for Bio Sub equity interests in a future transaction is subject to market fluctuations, potentially affecting future divestment value.

Future Outlook

The company intends to complete a private placement offering of up to $120.9 million to support its operations. Post-merger, the Bio Business will continue the clinical development of Apitox, an intradermally administered bee venom-based toxin. The Acquiror will also implement a 1-for-10 reverse stock split and increase shares available under its 2024 Equity Incentive Plan.

Management Comments

• The errors were clerical in nature and did not reflect the intent of the parties.
• No other material terms of the transaction or disclosures in the Original Report are being amended.
• No other material terms of the Merger Agreement are amended or modified.

Industry Context

This amendment relates to a merger within the biopharmaceutical sector, specifically involving a clinical-stage company focused on bee venom-based toxins (Apitox). The capital raise and equity restructuring are common mechanisms in this industry to fund research, development, and commercialization efforts, especially for companies at the clinical stage. The focus on a specific therapeutic area (Apitox) suggests a niche market strategy within the broader pharmaceutical landscape.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Erik Emerson, as Bio Business Representative, has specific rights and responsibilities related to the Bio Sub and its operations, including monitoring compliance and enforcement rights.
• Erik Emerson is also appointed President of Acquiror and CEO of Bio Sub.
• The Side Letter Agreement between Acquiror, Bio Sub, and the Company dictates the allocation of private placement proceeds.
• An irrevocable proxy is granted to the Bio Sub Representative for voting Bio Sub shares owned by Acquiror upon termination of the Interim Period.

Stakeholder Impact

• Shareholders (Acquiror): Will experience a 1-for-10 reverse stock split. Their ownership percentage will be significantly diluted by the issuance of preferred stock to MindWave shareholders, who will collectively hold 90.9% of the combined entity on a fully diluted basis.
• Shareholders (MindWave): Will receive Acquiror Preferred Stock, representing 90.9% of the combined entity's equity on a fully diluted basis, a substantial increase from the previously stated 61%.
• Employees (Acquiror & MindWave): Changes in management (new CEO for Acquiror, new President Erik Emerson) and potential expansion of equity incentive plans could impact employee morale and retention. The Bio Business employees will continue their work under Bio Sub.
• Investors (Senior Convertible Notes): Benefit from clarified terms, expanded notification rights, and an extended closing date for their investment.
• Customers/Suppliers: No direct impact mentioned, but successful integration and financing could lead to more stable operations.

Next Steps

• Acquiror to prepare and file an Information Statement with the SEC regarding the Written Consent, Proposals, and Merger.
• Acquiror to respond to SEC comments on the Information Statement and disseminate the Definitive Information Statement to stockholders.
• Expiration of a 20-calendar day waiting period after mailing the Definitive Information Statement.
• Implementation of Proposals approved by Written Consent (Action Effective Time), including the conversion of Series A Convertible Preferred Stock.
• Acquiror to file the Charter Amendment with the Delaware Secretary of State to implement the 1-for-10 Reverse Stock Split.
• Acquiror to cause the Acquiror Preferred Stock to be converted into Acquiror Common Stock after the Reverse Stock Split.
• Acquiror to obtain conditional approval of its listing application from NYSE American.
• Acquiror to file a registration statement on Form S-8 to register additional shares under the 2024 Equity Incentive Plan within five business days of the Action Effective Time.
• Acquiror to use best efforts to consummate a private placement offering of up to $120.9 million.
• If private placement not consummated by closing, Bio Sub to deposit $2.5 million loan to the Company within 2 business days.
• Transfer of Acquiror's pre-closing assets and liabilities to Bio Sub.
• Bio Business to be preserved and operated consistent with past practices for six months post-closing.

Key Dates

Recommendation

The filing primarily concerns corrections of clerical errors and clarifications of existing agreements, which are generally neutral events. While the significant increase in MindWave's post-merger ownership (from 61% to 90.9% fully diluted) is a material change, it is presented as a correction to the original intent, not a new development. The capital raise efforts and operational plans for the Bio Business are positive for future growth, but the immediate impact on valuation is unclear without further financial details. The reverse stock split is a technical adjustment. Given the nature of corrections and forward-looking financing, a 'hold' recommendation is appropriate as investors await further clarity on the combined entity's financial performance and successful execution of the capital raise and integration.

Keywords

Merger Agreement Amendment, SEC Filing, 8-K/A, Apimeds Pharmaceuticals, MindWave Innovations, Securities Purchase Agreement, Clerical Error Correction, Corporate Governance, Capitalization Change, Preferred Stock, Common Stock, Reverse Stock Split, Private Placement, Biopharmaceutical, Apitox, NYSE American Listing, Equity Incentive Plan, Corporate Merger, Financial Reporting, Risk Management